Us Bancorp \De\ Biotechnology

Us Bancorp \De\

$77.3 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
TNGX Tango Therapeutics, Inc.	$268M	$2,000 0.0% of portfolio	265	Q3 2024 Reduced 53.26%
PROK Prokidney Corp Ord Shs Cl A(Cy	$106M	$1,000 0.0% of portfolio	1,013	Q3 2024 Reduced 52.19%
ANIX Anixa Biosciences Inc	$86.5M	$1,000 0.0% of portfolio	400	Q2 2022 Reduced 97.07%
CRBU Caribou Biosciences, Inc.	$91.9M	$1,000 0.0% of portfolio	751	Q3 2024 Reduced 48.1%
CGEM Cullinan Oncology, Inc.	$481M	$1,000 0.0% of portfolio	117	Q3 2024 Added 11.43%
IGMS Igm Biosciences, Inc.	$49M	$1,000 0.0% of portfolio	90	Q3 2024 Added 429.41%
LYEL Lyell Immunopharma, Inc.	$149M	$1,000 0.0% of portfolio	1,165	Q1 2024 New
MDXG Mimedx Group, Inc.	$999M	$1,000 0.0% of portfolio	200	Q4 2022 Reduced 55.65%
OCGN Ocugen, Inc.	$169M	$1,000 0.0% of portfolio	1,638	Q3 2024 Reduced 53.55%
TSHA Taysha Gene Therapies, Inc.	$72.5M	$1,000 0.0% of portfolio	860	Q3 2024 Reduced 94.65%
TNYA Tenaya Therapeutics, Inc.	$51.7M	$1,000 0.0% of portfolio	847	Q3 2024 New
ZNTL Zentalis Pharmaceuticals, Inc.	$127M	$1,000 0.0% of portfolio	383	Q3 2024 Reduced 62.04%
URGN Uro Gen Pharma Ltd.	$234M	$0 0.0% of portfolio	47	Q3 2024 Reduced 72.35%
ATHA Athira Pharma, Inc.	$20.4M	$0 0.0% of portfolio	815	Q1 2024 New
CCCC C4 Therapeutics, Inc.	$178M	$0 0.0% of portfolio	38	Q3 2024 New
CABA Cabaletta Bio, Inc.	$72.5M	$0 0.0% of portfolio	191	Q3 2024 Reduced 54.2%
CARA Cara Therapeutics, Inc.	$322M	$0 0.0% of portfolio	35	Q2 2023 Reduced 75.69%
CDXS Codexis, Inc.	$322M	$0 0.0% of portfolio	160	Q2 2023 Reduced 44.25%
ELYM Eliem Therapeutics, Inc.	$109M	$0 0.0% of portfolio	141	Q3 2024 New
ERAS Erasca, Inc.	$238M	$0 0.0% of portfolio	84	Q3 2024 New
INZY Inozyme Pharma, Inc.	$57M	$0 0.0% of portfolio	44	Q3 2024 New
MREO Mereo Biopharma Group PLC	$369M	$0 0.0% of portfolio	13	Q2 2024 Reduced 96.85%
NKTX Nkarta, Inc.	$121M	$0 0.0% of portfolio	45	Q3 2024 New
PBYI Puma Biotechnology, Inc.	$137M	$0 0.0% of portfolio	200	Q3 2021 Reduced 60.78%
RAPT Rapt Therapeutics, Inc.	$35M	$0 0.0% of portfolio	11	Q1 2023 Reduced 82.81%
SGMO Sangamo Therapeutics, Inc	$182M	$0 0.0% of portfolio	23	Q3 2024 Reduced 95.7%
SVRA Savara Inc	$303M	$0 0.0% of portfolio	114	Q2 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	18,680	Q3 2024 Added 11,951.61%
SPRO Spero Therapeutics, Inc.	$30.5M	$0 0.0% of portfolio	151	Q2 2022 Reduced 86.88%
STRO Sutro Biopharma, Inc.	$106M	$0 0.0% of portfolio	53	Q3 2024 Reduced 99.56%
XBIT X Biotech Inc.	$114M	$0 0.0% of portfolio	100	Q2 2024 New
YMAB Y M Abs Therapeutics, Inc.	$273M	$0 0.0% of portfolio	17	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.